Sodium–Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia: A Population-Based Cohort Study
The DOI matches its Crossref record, with a small difference in title or year; 61 of the 61 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Both sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may have neuroprotective effects in patients with type 2 diabetes (T2D). However, their comparative effectiveness in preventing dementia remains uncertain. OBJECTIVE: To compare the risk for dementia between SGLT2 inhibitors and dulaglutide (a GLP-1 RA). DESIGN: Target trial emulation study. SETTING: Nationwide health care data of South Korea obtained from the National Health Insurance Service between 2010 and 2022. PATIENTS: Patients aged 60 years or older who have T2D and are initiating treatment with SGLT2 inhibitors or dulaglutide. MEASUREMENTS: The primary outcome was the presumed clinical onset of dementia. The date of onset was defined as the year before the date of dementia diagnosis, assuming that the time between the onset of dementia and diagnosis was 1 year. The 5-year risk ratios and risk differences comparing SGLT2 inhibitors with dulaglutide were estimated in a 1:2 propensity score-matched cohort adjusted for confounders. RESULTS: Overall, 12 489 patients initiating SGLT2 inhibitor treatment (51.9% dapagliflozin and 48.1% empagliflozin) and 1075 patients initiating dulaglutide treatment were included. In the matched cohort, over a median follow-up of 4.4 years, the primary outcome event occurred in 69 participants in the SGLT2 inhibitor group and 43 in the dulaglutide group. The estimated risk difference was -0.91 percentage point (95% CI, -2.45 to 0.63 percentage point), and the estimated risk ratio was 0.81 (CI, 0.56 to 1.16). LIMITATION: levels or duration of diabetes; the study is not representative of newer drugs, including more effective GLP-1 RAs; and the onset of dementia was not measured directly. CONCLUSION: Under conventional statistical criteria, a risk for dementia between 2.5 percentage points lower and 0.6 percentage point greater for SGLT2 inhibitors than for dulaglutide was estimated to be highly compatible with the data from this study. However, whether these findings generalize to newer GLP-1 RAs is uncertain. Thus, further studies incorporating newer drugs within these drug classes and better addressing residual confounding are required. PRIMARY FUNDING SOURCE: Ministry of Food and Drug Safety of South Korea.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
1 retracted
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430 · cited 2×
“A meta-analysis incorporating 64 RCTs found semaglu-tide and liraglutide to be the most effective GLP-1 RAs for inducing weight loss, and obesity is considered one of the top risk factors for dementia (31, 48, 49).”
RetractedAustin, P. C. (2011) · Multivariate Behavioral Research · doi:10.1080/00273171.2011.568786 · Cited by 12,242 · cited 1×
“We calculated the PS, de fi ned as the predicted probability of the treatment of interest (SGLT2 inhibitors or dula-glutide), for each patient using a multivariable logistic regression model conditional on prede fi ned baseline confounders (43).”
Austin, P. C. (2009) · Statistics in Medicine · doi:10.1002/sim.3697 · Cited by 6,758 · cited 1×
“…and the numbers and frequencies for categorical variables were provided, and absolute standardized mean differences were calculated to assess the balance of confounders between the groups with an absolute standardized mean difference greater than 0.1, indicating a signi fi - cant imbalance (45).”
InfluentialFeigin, V. L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., Culpepper, W. J., Dorsey, E. R., Elbaz, A., Ellenbogen, R. G., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30499-x · Cited by 5,644
Nichols, E., Steinmetz, J. D., Vollset, S. E., Fukutaki, K., Chalek, J., Abd-Allah, F., Abdoli, A., Abualhasan, A., Abu-Gharbieh, E., Akram, T. T., et al. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00249-8 · Cited by 5,575
Epidemiology of Type 2 Diabetes – Global Burden of Disease and Forecasted Trends
Khan, M. A. B., Hashim, M. J., King, J. K., Govender, R. D., Mustafa, H., & Al Kaabi, J. (2019) · Journal of Epidemiology and Global Health · doi:10.2991/jegh.k.191028.001 · Cited by 3,130
mTOR is a key modulator of ageing and age-related disease
Johnson, S. C., Rabinovitch, P. S., & Kaeberlein, M. (2013) · Nature · doi:10.1038/nature11861 · Cited by 1,676
Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · cited 1×
“…antidiabetic drugs, sodium – glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have gained considerable attention due to additional, remarkable bene fi ts to the cardiovascular and renal systems beyond the drugs ’ glucose-lowering effects (10, 11).”
McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies
Cukierman, T., Gerstein, H. C., & Williamson, J. D. (2005) · Diabetologia · doi:10.1007/s00125-005-0023-4 · Cited by 1,049
Twarda-Clapa, A., Olczak, A., Białkowska, A. M., & Koziołkiewicz, M. (2022) · Cells · doi:10.3390/cells11081312 · Cited by 746
Diabetes mellitus and risk of dementia: A meta‐analysis of prospective observational studies
Gudala, K., Bansal, D., Schifano, F., & Bhansali, A. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12087 · Cited by 727 · cited 1×
“Type 2 diabetes (T2D) is an important risk factor for dementia: People with T2D have signi fi cantly higher risk for dementia than those without (3 – 5).”
Xue, M., Xu, W., Ou, Y.-N., Cao, X.-P., Tan, M.-S., Tan, L., & Yu, J.-T. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100944 · Cited by 715
McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698 · cited 1×
“In murine models, GLP-1 RAs not only improved brain vascular health but also prevented neurodegenerative development by stimulating neuronal proliferation in the dentate gyrus of the hippocampus, reducing amyloid-b plaque formation, and enhancing synaptic plasticity (19 – 22).”
Desai, R. J., & Franklin, J. M. (2019) · BMJ · doi:10.1136/bmj.l5657 · Cited by 657 · cited 2×
“The analyses were the same as for the target trial except that the 1:2 propensity score (PS) matching method was used to adjust for confounders (42).”
Gasparini, L., Gouras, G. K., Wang, R., Gross, R. S., Beal, M. F., Greengard, P., & Xu, H. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-08-02561.2001 · Cited by 492
Gejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00108 · Cited by 480 · cited 1×
“In contrast, liraglutide could not prevent the accumulation of amyloid-b compared with placebo after 26-week treatment in patients with Alzheimer disease (53).”
Lin, B., Koibuchi, N., Hasegawa, Y., Sueta, D., Toyama, K., Uekawa, K., Ma, M., Nakagawa, T., Kusaka, H., & Kim-Mitsuyama, S. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0148-1 · Cited by 423
An introduction to multiplicity issues in clinical trials: the what, why, when and how
Li, G., Taljaard, M., Van den Heuvel, E. R., Levine, M. A., Cook, D. J., Wells, G. A., Devereaux, P. J., & Thabane, L. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw320 · Cited by 381 · cited 1×
“Furthermore, fi ndings for secondary outcomes in this study should be considered subsidiary because of potential multiplicity issues (63).”
Oxidative Stress and Programmed Cell Death in Diabetic Neuropathy
VINCENT, A. M., BROWNLEE, M., & RUSSELL, J. W. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb02108.x · Cited by 361 · cited 1×
“Chronic hyperglycemia and insulin resistance in T2D might contribute to the development of dementia through various biological pathways, including oxidative stress, in fl ammation, and cerebral impaired insulin signaling (6 – 8).”
Cukierman-Yaffe, T., Gerstein, H. C., Colhoun, H. M., Diaz, R., García-Pérez, L.-E., Lakshmanan, M., Bethel, A., Xavier, D., Probstfield, J., Riddle, M. C., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30173-3 · Cited by 300 · cited 1×
“Furthermore, previous studies showed that both SGLT2 inhibitors and GLP-1 RAs may have effects in slowing cognitive decline and lowering the risk for dementia compared with placebo or other antidiabetic drugs (that is, dipeptidyl peptidase-4 inhibitors) (23 – 26).”
Anxiety as a risk factor of Alzheimer's disease and vascular dementia
Becker, E., Orellana Rios, C. L., Lahmann, C., Rücker, G., Bauer, J., & Boeker, M. (2018) · The British Journal of Psychiatry · doi:10.1192/bjp.2018.173 · Cited by 226 · cited 1×
“In addition, the trial excluded patients with a history of psychiatric disorders who are at high risk for developing dementia, which may result in an inability to accurately re fl ect the risk for dementia in real-world patients receiving the study drugs (28 – 33).”
Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases
Grieco, M., Giorgi, A., Gentile, M. C., d’Erme, M., Morano, S., Maras, B., & Filardi, T. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01112 · Cited by 218 · cited 1×
“…various mechanisms related to neuroprotective effects, such as reducing neuroin fl ammation, improving synaptic plasticity, and promoting neuronal survival (15, 16, 19, 20), several other possible mechanisms may explain the numerically lower incidence rate of dementia onset in SGLT2 inhibitor users.”
Lafay‐Chebassier, C., Paccalin, M., Page, G., Barc‐Pain, S., Perault‐Pochat, M. C., Gil, R., Pradier, L., & Hugon, J. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03187.x · Cited by 211
Nørgaard, C. H., Friedrich, S., Hansen, C. T., Gerds, T., Ballard, C., Møller, D. V., Knudsen, L. B., Kvist, K., Zinman, B., Holm, E., et al. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12268 · Cited by 206 · cited 1×
“In a nationwide, Danish, registry-based cohort study (25), use of GLP-1 RAs (mostly liraglutide) was also found to be associated with a lower incidence rate of dementia.”
Velosa, J., Delgado, A., Finger, E., Berk, M., Kapczinski, F., & de Azevedo Cardoso, T. (2020) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13153 · Cited by 188
Hierro-Bujalance, C., Infante-Garcia, C., del Marco, A., Herrera, M., Carranza-Naval, M. J., Suarez, J., Alves-Martinez, P., Lubian-Lopez, S., & Garcia-Alloza, M. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00607-4 · Cited by 181
Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment
Rizzo, M. R., Di Meo, I., Polito, R., Auriemma, M. C., Gambardella, A., di Mauro, G., Capuano, A., & Paolisso, G. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106062 · Cited by 178 · cited 1×
“Furthermore, growing evidence suggests that SGLT2 inhibitors and GLP-1 RAs may also have neuroprotective effects (12 – 14).”
Patterns of Care in the Early Stages of Alzheimer's Disease: Impediments to Timely Diagnosis
Knopman, D., Donohue, J. A., & Gutterman, E. M. (2000) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2000.tb02650.x · Cited by 170
Type 2 Diabetes, Cognition, and Dementia in Older Adults: Toward a Precision Health Approach
Cholerton, B., Baker, L. D., Montine, T. J., & Craft, S. (2016) · Diabetes Spectrum · doi:10.2337/ds16-0041 · Cited by 170 · cited 1×
“Chronic hyperglycemia and insulin resistance in T2D might contribute to the development of dementia through various biological pathways, including oxidative stress, in fl ammation, and cerebral impaired insulin signaling (6 – 8).”
Richmond-Rakerd, L. S., D’Souza, S., Milne, B. J., Caspi, A., & Moffitt, T. E. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.4377 · Cited by 146
Schizophrenia and risk of dementia: a meta-analysis study
Cai, L., & Huang, J. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s172933 · Cited by 141
Wu, C.-Y., Iskander, C., Wang, C., Xiong, L. Y., Shah, B. R., Edwards, J. D., Kapral, M. K., Herrmann, N., Lanctôt, K. L., Masellis, M., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1705 · Cited by 139
Zhao, L., Li, Z., Vong, J. S. L., Chen, X., Lai, H.-M., Yan, L. Y. C., Huang, J., Sy, S. K. H., Tian, X., Huang, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18249-3 · Cited by 126
Self-citationThe pathway to dementia diagnosis
Speechly, C. M., Bridges‐Webb, C., & Passmore, E. (2008) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2008.tb02140.x · Cited by 125
The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
Du, H., Meng, X., Yao, Y., & Xu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1033479 · Cited by 125
Gimson, A., Schlosser, M., Huntley, J. D., & Marchant, N. L. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-019399 · Cited by 122
Wiciński, M., Wódkiewicz, E., Górski, K., Walczak, M., & Malinowski, B. (2020) · Pharmaceuticals · doi:10.3390/ph13110379 · Cited by 110
Wilkinson, D., Stave, C., Keohane, D., & Vincenzino, O. (2004) · Journal of International Medical Research · doi:10.1177/147323000403200207 · Cited by 99
Vosoughi, K., Atieh, J., Khanna, L., Khoshbin, K., Prokop, L. J., Davitkov, P., Murad, M. H., & Camilleri, M. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101213 · Cited by 97 · cited 1×
“A meta-analysis incorporating 64 RCTs found semaglu-tide and liraglutide to be the most effective GLP-1 RAs for inducing weight loss, and obesity is considered one of the top risk factors for dementia (31, 48, 49).”
Hayden, M., Grant, D., Aroor, A., & DeMarco, V. (2019) · Brain Sciences · doi:10.3390/brainsci9030057 · Cited by 93
Abdel-latif, R. G., Rifaai, R. A., & Amin, E. F. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01237-y · Cited by 92
Biessels, G. J., Verhagen, C., Janssen, J., van den Berg, E., Zinman, B., Rosenstock, J., George, J. T., Passera, A., Schnaidt, S., & Johansen, O. E. (2019) · Diabetes Care · doi:10.2337/dc19-0783 · Cited by 88 · cited 1×
“…with dipeptidyl peptidase-4 inhibitors (which showed no effect on cognitive performance in patients with T2D compared with placebo or sulfonylureas in 2 RCTs [46, 47]), dapagli fl o-zin and empagli fl ozin but not canagli fl ozin were associated with lower risk for dementia in patients with T2D.”
Arafa, N. M. S., Ali, E. H. A., & Hassan, M. K. (2017) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2017.08.013 · Cited by 74
Shaikh, S., Rizvi, S. M. D., Shakil, S., Riyaz, S., Biswas, D., & Jahan, R. (2016) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1319 · Cited by 70
Cheng, H., Zhang, Z., Zhang, B., Zhang, W., Wang, J., Ni, W., Miao, Y., Liu, J., & Bi, Y. (2022) · Diabetes Care · doi:10.2337/dc21-2064 · Cited by 70
Zhao, M., Lv, X., Maimaitirexiati, T., He, J., Luo, B., Chen, W., Wang, K., Gu, P., Kuang, W., Zhou, Y., et al. (2015) · International Psychogeriatrics · doi:10.1017/s1041610215000940 · Cited by 66
Blood Pressure Control and Dementia Risk in Midlife Patients With Atrial Fibrillation
Kim, D., Yang, P., Jang, E., Yu, H. T., Kim, T., Uhm, J., Kim, J., Sung, J., Pak, H., Lee, M., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.14388 · Cited by 64
The Carrot and the Stick: Benefits and Barriers in Getting a Diagnosis
Wackerbarth, S. B., & Johnson, M. M. S. (2002) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200210000-00002 · Cited by 62
Carpentier, N., Bernard, P., Grenier, A. M., & Guberman, N. (2010) · Social Science & Medicine · doi:10.1016/j.socscimed.2009.12.038 · Cited by 61
Xing, J., & Lu, J. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000445643 · Cited by 59
Khan, T. M., Khan, S. I., Akhtar, M., Ali, J., & Najmi, A. K. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105158 · Cited by 56
Biessels, G. J., Verhagen, C., Janssen, J., van den Berg, E., Wallenstein, G., Zinman, B., Espeland, M. A., & Johansen, O. E. (2021) · Diabetologia · doi:10.1007/s00125-021-05393-8 · Cited by 55 · cited 1×
“…with dipeptidyl peptidase-4 inhibitors (which showed no effect on cognitive performance in patients with T2D compared with placebo or sulfonylureas in 2 RCTs [46, 47]), dapagli fl o-zin and empagli fl ozin but not canagli fl ozin were associated with lower risk for dementia in patients with T2D.”
Ischemia as a common trigger for Alzheimer’s disease
Elman-Shina, K., & Efrati, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1012779 · Cited by 48 · cited 1×
“Another possible mechanism may be that SGLT2 inhibitors (such as empagli fl ozin) improved cerebral ischemia, which largely accelerates the onset of dementia (59 – 61).”
Stanciu, G. D., Rusu, R. N., Bild, V., Filipiuc, L. E., Tamba, B.-I., & Ababei, D. C. (2021) · Biomedicines · doi:10.3390/biomedicines9050576 · Cited by 47 · cited 1×
“…and empagli fl o-zin restored hyperactivated mTOR to a physiologically O RIGINAL R ESEARCH SGLT2 Inhibitors, Dulaglutide, and Risk for Dementia activated state in murine models, thereby accelerating the decline of brain function and preventing the onset or progression of Alzheimer disease (54 – 57).”
Mancinetti, F., Xenos, D., Fano, M. D., Mazzieri, A., Porcellati, F., Boccardi, V., & Mecocci, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102018 · Cited by 37
Parallel increase in p70 kinase activation and tau phosphorylation (S262) with Aβ overproduction
Zhou, X.-W., Tanila, H., & Pei, J.-J. (2008) · FEBS Letters · doi:10.1016/j.febslet.2007.11.078 · Cited by 31
Time from Symptom Debut to Dementia Assessment by the Specialist Healthcare Service in Norway
Helvik, A., Engedal, K., Benth, J. Š., & Selbæk, G. (2018) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000487233 · Cited by 31
Obesity Is Now the Top Modifiable Dementia Risk Factor in the US
Slomski, A. J. (2022) · JAMA · doi:10.1001/jama.2022.11058 · Cited by 31
Mehan, S., Bhalla, S., Siddiqui, E. M., Sharma, N., Shandilya, A., & Khan, A. (2022) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s247153 · Cited by 29 · cited 1×
“Furthermore, growing evidence suggests that SGLT2 inhibitors and GLP-1 RAs may also have neuroprotective effects (12 – 14).”
Newer glucose‐lowering drugs and risk of dementia: A meta‐analysis of cardiovascular outcome trials
Tang, H., Niu, S., Brown, J. D., Wei, J., Shao, H., Bian, J., & Guo, J. S. (2022) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17895 · Cited by 13 · cited 1×
“Furthermore, previous studies showed that both SGLT2 inhibitors and GLP-1 RAs may have effects in slowing cognitive decline and lowering the risk for dementia compared with placebo or other antidiabetic drugs (that is, dipeptidyl peptidase-4 inhibitors) (23 – 26).”
Cited by
Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders
Giorgi, R. D., Ghenciulescu, A., Yotter, C. N., Taquet, M., & Koychev, I. G. (2025) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2024-335593 · Cited by 47
Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity
Lin, H.-T., Tsai, Y.-F., Liao, P.-L., & Wei, J. C.-C. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.21016 · Cited by 43
Mechanisms underlying cognitive impairment and management strategies in type 2 diabetes
Chen, X., Huang, Y., & Xiong, X. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1655768 · Cited by 37
Sun, M., Wang, X., Lu, Z., Yang, Y., Lv, S., Miao, M., Chen, W., Wu, S., & Zhang, J. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101623 · Cited by 24
Inoue, K., Saliba, D., Gotanda, H., Moin, T., Mangione, C. M., Klomhaus, A. M., & Tsugawa, Y. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02648 · Cited by 22
Metadata
- Authors
- Hong, B., Bea, S., Ko, H. Y., Kim, W. J., Cho, Y. M., & Shin, J.-Y.
- Affiliations
- Sungkyunkwan University (KR)
- Brigham and Women's Hospital (US)
- Yonsei University (KR)
- Seoul National University (KR)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2024-10
- Volume
- 177
- Issue
- 10
- Pages
- 1319-1329
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W4401873288
- Cited by
- 33
- References
- 61
- Citations by year
- 2026: 7 · 2025: 25 · 2024: 1
- FWCI
- 10.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- SGLT2 inhibitors, dulaglutide, dementia risk, type 2 diabetes, GLP-1 receptor agonists, dapagliflozin, empagliflozin, neuroprotection, older adults, target trial emulation, propensity score matching, dementia onset, drug comparison
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Aged, Benzhydryl Compounds, Dementia, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Glucosides, Humans, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Male, Middle Aged, Recombinant Fusion Proteins, Risk Factors, Cohort Studies, Republic of Korea, Propensity Score
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.